Table 1 The relationship between the expression of NTN4 and clinicopathological data.
From: NTN4 as a prognostic marker and a hallmark for immune infiltration in breast cancer
Characteristic | NTN4 mRNA | P | |
|---|---|---|---|
Low(n = 541) | High(n = 542) | ||
Age (years) | 0.035 | ||
Median (IQR) | 57 (48, 66) | 60 (49, 68) | 0.012 |
< = 60 | 318 (29.4%) | 283 (26.1%) | |
> 60 | 223 (20.6%) | 259 (23.9%) | |
T stage, n (%) | < 0.001 | ||
T1 | 113 (10.5%) | 164 (15.2%) | |
T2 | 349 (32.3%) | 280 (25.9%) | |
T3 | 60 (5.6%) | 79 (7.3%) | |
T4 | 17 (1.6%) | 18 (1.7%) | |
N stage, n (%) | 0.653 | ||
N0 | 258 (24.2%) | 256 (24.1%) | |
N1 | 179 (16.8%) | 179 (16.8%) | |
N2 | 61 (5.7%) | 55 (5.2%) | |
N3 | 33 (3.1%) | 43 (4%) | |
M stage, n (%) | 1.000 | ||
M0 | 452 (49%) | 450 (48.8%) | |
M1 | 10 (1.1%) | 10 (1.1%) | |
Menopause status, n (%) | 0.916 | ||
Pre | 117 (12%) | 112 (11.5%) | |
Peri | 20 (2.1%) | 20 (2.1%) | |
Post | 348 (35.8%) | 355 (36.5%) | |
Histological type, n (%) | < 0.001 | ||
Infiltrating Ductal Carcinoma | 440 (45%) | 332 (34%) | |
Infiltrating Lobular Carcinoma | 52 (5.3%) | 153 (15.7%) | |
Pathologic stage, n (%) | 0.004 | ||
Stage I | 71 (6.7%) | 110 (10.4%) | |
Stage II | 335 (31.6%) | 284 (26.8%) | |
Stage III | 117 (11%) | 125 (11.8%) | |
Stage IV | 8 (0.8%) | 10 (0.9%) | |
PR status, n (%) | < 0.001 | ||
Negative | 267 (25.8%) | 75 (7.3%) | |
Indeterminate | 3 (0.3%) | 1 (0.1%) | |
Positive | 245 (23.7%) | 443 (42.8%) | |
ER status, n (%) | < 0.001 | ||
Negative | 202 (19.5%) | 38 (3.7%) | |
Indeterminate | 1 (0.1%) | 1 (0.1%) | |
Positive | 313 (30.2%) | 480 (46.4%) | |
HER2 status, n (%) | 0.438 | ||
Negative | 264 (36.3%) | 294 (40.4%) | |
Indeterminate | 7 (1%) | 5 (0.7%) | |
Positive | 82 (11.3%) | 75 (10.3%) | |
